Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DABIGATRAN ETEXILATE Cause Abdominal pain? 289 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 289 reports of Abdominal pain have been filed in association with DABIGATRAN ETEXILATE (dabigatran etexilate). This represents 0.8% of all adverse event reports for DABIGATRAN ETEXILATE.

289
Reports of Abdominal pain with DABIGATRAN ETEXILATE
0.8%
of all DABIGATRAN ETEXILATE reports
65
Deaths
194
Hospitalizations

How Dangerous Is Abdominal pain From DABIGATRAN ETEXILATE?

Of the 289 reports, 65 (22.5%) resulted in death, 194 (67.1%) required hospitalization, and 28 (9.7%) were considered life-threatening.

Is Abdominal pain Listed in the Official Label?

Yes, Abdominal pain is listed as a known adverse reaction in the official FDA drug label for DABIGATRAN ETEXILATE.

What Other Side Effects Does DABIGATRAN ETEXILATE Cause?

Gastrointestinal haemorrhage (4,081) Cerebrovascular accident (2,175) Fall (1,786) Ischaemic stroke (1,581) Anaemia (1,412) Haemorrhage (1,324) Death (1,025) Rectal haemorrhage (964) Cerebral haemorrhage (946) Upper gastrointestinal haemorrhage (861)

What Other Drugs Cause Abdominal pain?

ADALIMUMAB (10,983) VEDOLIZUMAB (6,401) INFLIXIMAB (6,059) METHOTREXATE (5,002) LEVONORGESTREL (4,054) ACETAMINOPHEN (4,001) PREDNISONE (3,704) RITUXIMAB (3,364) ETANERCEPT (2,524) TOCILIZUMAB (2,485)

Which DABIGATRAN ETEXILATE Alternatives Have Lower Abdominal pain Risk?

DABIGATRAN ETEXILATE vs DABRAFENIB DABIGATRAN ETEXILATE vs DABRAFENIB\TRAMETINIB DABIGATRAN ETEXILATE vs DACARBAZINE DABIGATRAN ETEXILATE vs DACLATASVIR DABIGATRAN ETEXILATE vs DACLIZUMAB

Related Pages

DABIGATRAN ETEXILATE Full Profile All Abdominal pain Reports All Drugs Causing Abdominal pain DABIGATRAN ETEXILATE Demographics